AstraZeneca (LSE:AZN) shares moved lower on Friday after an independent advisory panel to the U.S. Food and Drug Administration voted against backing the risk-benefit profile of its experimental breast cancer therapy, camizestrant.
The stock declined 1.6% in London by 07:37 GMT.
Advisory Committee Vote Raises Regulatory Concerns
The FDA’s Oncologic Drugs Advisory Committee voted 6–3 against the oral treatment, which is being developed as a first-line option for a subtype of breast cancer linked to a specific genetic mutation. The panel determined that the drug did not demonstrate a “meaningful benefit” for patients whose disease had not progressed on existing therapies.
Although such advisory votes are not legally binding, regulators often align with the panel’s recommendations. A final ruling from the FDA is expected at a later date.
Analysts Flag Impact on Approval Prospects
The outcome introduces “regulatory overhang and a dent to investor sentiment,” according to analysts at Morgan Stanley led by Sarita Kapila.
“We see a decreased likelihood of approval in the SERENA-6 setting following the 6–3 negative ODAC vote, though approval remains possible,” they noted.
Company Response and Trial Data
AstraZeneca said it was “disappointed” with the panel’s decision but maintained confidence in both its clinical data and the drug’s potential to benefit patients.
Trial results showed that camizestrant extended the time before disease progression by more than six months. When used alongside other cancer treatments, patients experienced a median progression-free period of 16 months, compared with 9.2 months under the current standard of care.
Leave a Reply